Steroid inhalers cut half inch off height
WASHINGTON U. – ST. LOUIS (US) — Kids who inhale steroid drugs for asthma end up a bit shorter as adults than their peers who didn’t use the medication, a new study shows.
The study involved more than 1,000 children ages 5-12 who were treated for mild to moderate asthma as part of the Childhood Asthma Management Program (CAMP) clinical trial. The children received treatment for more than four years at eight centers, including Washington University School of Medicine.
They were divided into three groups: one received twice-daily budesonide, an inhaled corticosteroid medication; a second group received nedocromil, an inhaled non-steroid medication; and a third group received a placebo. All children received albuterol, a fast-acting drug for relief of acute asthma symptoms, and oral corticosteroids as needed for asthma symptoms.
The researchers followed 943 participants in the trial at regular intervals until they reached adult height. Females were considered to be at adult height at age 18 or older and males at age 20 or older, Strunk says. In the first 4 and a half years after the end of the trial, researchers took patients’ height and weight every six months. Over the next eight years, height and weight were measured once or twice a year.
The mean adult height was about one-half inch, or 1.2 centimeters, shorter in the group that received budesonide than in the patients who received nedocromil or placebo. The patients who experienced the slower growth were primarily between 5-11 years old when they began using budesonide.
The slower growth took place only in the first two years of the four-year study. As the study progressed, the children who took the budesonide remained one-half inch shorter through adulthood than the children who did not use the drug, says the study’s senior author Robert C. Strunk, professor of pediatrics at Washington University School of Medicine in St. Louis, who treats children with asthma at St. Louis Children’s Hospital.
“This was surprising because in previous studies, we found that the slower growth would be temporary, not affecting adult height,” Strunk says. “But none of those studies followed patients from the time they entered the study until they had reached adult height.”
Strunk, CAMP study chair, says researchers considered various factors that also might have contributed to the slower growth rate, including gender, age at the time the child entered the trial, how long the child had had asthma, as well as ethnicity, severity of asthma and reactivity to a skin test for allergies.
“We found it made no difference if they were boys or girls or how long they had had asthma, or any other of these factors,” Strunk says. “We also looked at the height of the parents, and that didn’t have any impact, either.”
Pediatric asthma specialists at St. Louis Children’s Hospital keep a close watch on the growth of their patients who use inhaled steroids, Strunk says. They are measured at every visit, and physicians keep a growth curve.
“If a child is not growing as they should, we may reduce their steroid dose,” he says. “But we think that the half-inch of lowered adult height must be balanced against the well-established benefit of inhaled corticosteroids in controlling persistent asthma. We will use the lowest effective dose to control symptoms to minimize concerns about effects on adult height.”
Inhaled corticosteroids such as budesonide, are the most effective form of anti-inflammatory treatment for asthma, which affects 9.4 percent of US children. The drugs control symptoms and improve pulmonary function.
Results from the original CAMP trial, begun in the mid-1990s, showed that using budesonide twice daily led to fewer hospitalizations and urgent care visits, fewer days in which additional asthma medications were needed, and a reduced need for albuterol.
Using nedocromil twice daily reduced urgent care visits and courses of oral steroids for severe symptoms but did not affect the number of hospitalizations, symptoms, or airway responsiveness.
You are free to share this article under the Creative Commons Attribution-NoDerivs 3.0 Unported license.